Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

University of Macau | Macau

Dr. Xiaowen Mao, M.D., Ph.D., is an Assistant Professor at the State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, where she leads translational research on cancer biology, immunotherapy, and tumor microenvironment modulation. She earned her Ph.D. in Biomedical Sciences from the University of Hong Kong and her B.Sc. in Clinical Medicine from Shanghai Jiao Tong University, China. Her research focuses on extracellular vesicles, immune homeostasis, metabolic reprogramming in tumors, and hepatocellular carcinoma metastasis, integrating molecular, cellular, and translational approaches. Dr. Xiaowen Mao has led several high-impact projects as principal investigator, funded by the Health and Medical Research Fund, National Natural Science Foundation Young Scientist Fund, and FDCT Innovation and Technology Promotion. Her significant contributions include the development of broadly potent neutralizing antibodies targeting Nidogen 1 to inhibit tumor growth, elucidation of extracellular vesicle-mediated metabolic reprogramming in tumors, and advances in dendritic cell vaccine strategies. She holds a U.S. patent on Nidogen 1 as a diagnostic and therapeutic target for hepatocellular carcinoma, serves as Guest Editor for Frontiers in Endocrinology, and is an ad-hoc reviewer for multiple high-impact journals. According to Scopus, she has 31 publications, 1,114 citations by 1,010 documents, and an h-index of 20. Dr. Xiaowen Mao’s work bridges fundamental research and clinical translation, delivering innovative therapies and advancing precision medicine in oncology, while demonstrating a profound impact on cancer biology, immunotherapy, and translational research.

Profile: Scopus

Featured Publications

  • Xue, T. M., Yeung, C. L. S., Mao, X. W., Tey, S. K., Lo, K. W., Tang, H. N., Yun, J. P., & Yam, J. W. P. (2025). Development of a broadly potent neutralizing antibody targeting Nidogen 1 effectively inhibits cancer growth and metastasis in preclinical tumor models. Journal of Translational Internal Medicine. https://doi.org/10.1515/jtim-2025-0008

  • Xia, L., Li, C. G., Zhao, J., Sun, Q. C., & Mao, X. W.* (2025). Rebalancing immune homeostasis in combating disease: The impact of medicine food homology plants and gut microbiome. Phytomedicine, 136, 156150. https://doi.org/10.1016/j.phymed.2025.156150

  • Chen, Z., Yam, J. W. P., & Mao, X. W.* (2024). The multifaceted roles of small extracellular vesicles in metabolic reprogramming in the tumor microenvironments. Proteomics, e2300021. https://doi.org/10.1002/pmic.202300021

  • Lee, K. W., Yam, J. W. P., & Mao, X. W.* (2023). Dendritic cell vaccines: A shift from conventional approach to new generations. Cells, 12(2147). https://doi.org/10.3390/cells12172147

  • Li, S., Delvecchio, M., Ramkumar, K., Mao, X. W., Sun, X. D., & Guo, S. Z. (2023). Editorial: Clinical and genetic determinants of diabetes and complications. Frontiers in Endocrinology.

Zhanbo Qu | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Zhanbo Qu | Medicine | Best Researcher Award

Huzhou central hospital | China

Dr. Qu Zhanbo is a dedicated medical professional at Huzhou Central Hospital, with a focus on microbiology, oncology, and gastroenterology. As a researcher, Dr. Qu has made significant contributions to the scientific community, publishing multiple papers in esteemed journals. His academic journey is marked by exceptional achievements, including being recognized as a top graduate innovative talent during his master’s studies.

Professional profile👤

ORCID

Strengths for the Awards✨

  • Research Productivity: Qu Zhanbo has published 2 SCI papers as the first author, 3 SCI papers as a total of first author, and contributed to 16 SCI papers overall. This demonstrates consistent research output and collaboration.

  • Interdisciplinary Focus: His research spans microbiology, oncology, and gastroenterology — fields with significant impact on healthcare, especially in understanding colorectal cancer risk.

  • Recognition and Innovation: Awarded as a top graduate Innovative Talent during his master’s studies, reflecting early recognition for his research potential.

  • Patent Development: Involved in the development of dissolving microneedles of Clostridium butyricum and oxaliplatin, indicating a focus on translational research and innovation.

  • Diverse Publications: Contributions to reputable journals like Aging and Disease, Aging-US, Digestion, and Microbial Biotechnology highlight his research’s acceptance in well-regarded scientific communities.

Education 🎓

Dr. Qu Zhanbo pursued his medical education with a deep interest in understanding complex diseases and their microbial interactions. His academic path laid the foundation for his subsequent research endeavors, where he explored the intersection of microbiology and oncology.

Experience 💼

Currently serving at Huzhou Central Hospital, Dr. Qu combines clinical practice with groundbreaking research. His work spans various domains, including the association of Peptostreptococcus stomatis with colorectal cancer risk. Over the years, he has authored multiple SCI papers and contributed extensively to scientific literature, showcasing his expertise and commitment to advancing medical knowledge.

Research Interests On Medicine🔬

Dr. Qu’s research interests lie at the crossroads of microbiology, oncology, and gastroenterology. His investigations delve into microbial influences on cancer development, aiming to uncover novel insights that could lead to improved diagnostic and therapeutic strategies.

Awards 🏆

Dr. Qu’s academic and research excellence have been recognized through several accolades, including being awarded as a top graduate innovative talent during his master’s studies. This honor reflects his exceptional contributions to scientific inquiry and innovation.

Publications 📖

Dr. Qu has an impressive publication record, with notable papers such as:

  1. Multiple primary malignancies and gut microbiome

    • Year: 2025

    • Authors: Yinhang Wu, Zhanbo Qu, Zheng Wu, Jing Zhuang, Yingchen Wang, Zefeng Wang, Jian Chu, Quan Qi, Shuwen Han

  2. Fecal occult blood affects intestinal microbial community structure in colorectal cancer

    • Year: 2025

    • Authors: Wu Guodong, Wu Yinhang, Wu Xinyue, Shen Hong, Chu Jian, Qu Zhanbo, Han Shuwen

  3. Aging Gut Microbiome in Healthy and Unhealthy Aging

    • Year: 2024

    • Authors: Zhanbo Qu

  4. Classification of Colorectal Cancer Subtypes Based on Endoplasmic Reticulum Stress

    • Year: 2024

    • Authors: Zhanbo Qu, Jian Chu, Yinhang Wu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  5. Escherichia coli on colorectal cancer: A two‐edged sword

    • Year: 2024 (October)

    • Authors: Chu Jian, Wu Yinhang, Zhuang Jing, Qu Zhanbo, Wang Zefeng, Shuwen Han

  6. Deep learning application in prediction of cancer molecular alterations based on pathological images: a bibliographic analysis via CiteSpace

    • Year: 2024 (October)

    • Authors: Yu Xiaojian, Qu Zhanbo, Chu Jian, Wang Zefeng, Liu Jian, Liu Jin, Pan Yuefen, Han Shuwen

  7. Third-generation PacBio sequencing to explore gut bacteria and gender in colorectal cancer

    • Year: 2024 (July)

    • Authors: Sheng Yu, Jian Chu, Yinhang Wu, Jing Zhuang, Zhanbo Qu, Yifei Song, Xinyue Wu, Shuwen Han

  8. Age and aging process alter the gut microbes

    • Year: 2024 (April 8)

    • Authors: Qu Zhanbo, Zhuang Jing, Han Shugao, Wu Yinhang, Chu Jian, Yu Xiang, Zhao Feimin, Liu Jian, Wu Xinyue, Wu Wei et al.

  9. Transcriptional profile and immune infiltration in colorectal cancer reveal the significance of inducible T‐cell costimulator as a crucial immune checkpoint molecule

    • Year: 2024 (March)

    • Authors: Jian Chu, Yinghang Wu, Zhanbo Qu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  10. Identification of enterotype and its predictive value for patients with colorectal cancer

  • Year: 2024 (February 27)

  • Authors: Li Qingbo, Zhuang Jing, Qu Zhanbo, Chu Jian, Song Yifei, Wu Yinhang, Han Shuwen

Conclusion 🔝

Dr. Qu Zhanbo stands out as a passionate researcher and dedicated doctor whose work bridges clinical practice and scientific exploration. His contributions to microbiology, oncology, and gastroenterology continue to shape the understanding of disease mechanisms and pave the way for future innovations in medical science.